A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs APR 246 (Primary)
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms APROC
- 16 Oct 2017 According to an Aprea media release, first patient has been enrolled.
- 17 May 2017 Status changed from not yet recruiting to recruiting.
- 23 Dec 2016 New trial record